GlassScriptPhysician profile
Bassem G Chahine
NPI 1518971753
$9,346.91
in general payments reported to CMS, 2019-2025
31 companies · $3,300 in 2025
The $3,300 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $125 · 2021: $579 · 2022: $1,383 · 2023: $1,321 · 2024: $1,940 · 2025: $3,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,536 · Consulting Fee: $25.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,536.07 |
| Consulting Fee | $25.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,608.63 | 2019-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $845.43 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $829.49 | 2019-2025 | Dupixent |
| Incyte Corporation | $675.65 | 2023-2025 | Opzelura |
| Genzyme Corporation | $601.40 | 2019-2025 | |
| Pfizer INC. | $590.37 | 2022-2025 | |
| Galderma Laboratories, L.P. | $574.33 | 2025 | Nemluvio |
| Alk-Abello, INC | $474.88 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Astrazeneca Pharmaceuticals LP | $464.24 | 2021-2025 | Airsupra, Fasenra |
| Genentech USA, INC. | $358.55 | 2023-2025 | Xolair |
| Adma Biomanufacturing LLC | $348.55 | 2022-2025 | |
| Optinose US, INC. | $275.23 | 2019-2025 | |
| Blueprint Medicines Corporation | $267.70 | 2022-2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $224.32 | 2023-2025 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $202.90 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $184.75 | 2025 | Neffy |
| Abbvie INC. | $143.15 | 2023-2025 | Rinvoq |
| Amgen INC. | $120.23 | 2022 | |
| Aimmune Therapeutics, INC. | $98.85 | 2020-2022 | |
| Csl Behring | $74.71 | 2022-2025 | Andembry, Hizentra |
| Teva Pharmaceuticals USA, INC. | $67.53 | 2019 | |
| Lilly USA, LLC | $58.00 | 2025 | Ebglyss |
| Leo Pharma INC. | $54.41 | 2023-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $46.59 | 2024-2025 | Xembify |
| Pharming Healthcare, INC. | $26.90 | 2022 | |
| Shire North American Group INC | $24.31 | 2019 | |
| Organon LLC | $23.90 | 2025 | Vtama |
| Cycle Pharmaceuticals INC | $22.80 | 2025 | Sajazir |
| Boston Scientific Corporation | $20.65 | 2022 | |
| Octapharma USA, INC. | $19.62 | 2024 | Panzyga |
| Tersera Therapeutics LLC | $18.84 | 2024 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Chahine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.